Termination in Entirety. 12.6.1 In the event of a termination of this Agreement in its entirety by AbbVie pursuant to Section 12.3.2 or by Galapagos pursuant to Section 12.2.1:
Termination in Entirety. In the event of a termination of this Agreement in its entirety by either Party:
Termination in Entirety. In the event of a termination of this Agreement in its entirety by Licensee pursuant to Section 12.3 or by Licensor pursuant to Section 12.2.1 or 12.4:
Termination in Entirety. 13.6.1 In the event of a termination of this Agreement in its entirety by AbbVie pursuant to Section 13.3.2 or by Licensor pursuant to Section 13.2.1 or 13.4:
Termination in Entirety. 10.6.1. In the event of a termination of this Agreement in its entirety pursuant to (a) Xynomic’s material breach pursuant to Section 10.2, (c) Section 10.3, (d) termination for convenience by Xynomic pursuant to Section 10.4, or (e) termination by Pharmacyclics pursuant to Section 10.5, then, to the extent permitted by Applicable Law:
Termination in Entirety. 12.6.1 In the event of a termination of this Agreement in its entirety by AbbVie pursuant to Section 12.3 (Additional Termination Rights by AbbVie) or by Ablynx pursuant to Sections 12.2.1 (Material Breach), 12.3.3 (Challenge to Ablynx Product Patents) or 12.4 (Termination for Insolvency):
Termination in Entirety. In the event of a termination (including expiration) of this Agreement in its entirety for any reason except where the Parties enter into the Exclusive License Agreement, and subject to the Collaboration Agreement, if and as applicable:
Termination in Entirety. The entire agreement can be terminated at any time upon the unanimous agreement of the parties.
Termination in Entirety. Upon termination of this Agreement with respect to all Licensed Gene Sequences, the Agreement shall be terminated in its entirety.
Termination in Entirety. Upon termination of this Agreement in its entirety by Xencor pursuant to Section 3.2(b) or by either Party pursuant to Section 9.2 or 9.3 (other than termination of this Agreement by INmune under Section 9.3(c)), all rights and licenses granted to INmune hereunder shall immediately terminate and, at Xencor’s option, exercisable upon written notice to INmune within 30 days after the effective date of such termination, the provisions set forth in Sections 9.4(b)(i), (ii) and (iii) shall apply to such Licensed Product. Upon such termination, each Party shall destroy all tangible items comprising, bearing or containing any Confidential Information of the other Party that are in its or its Affiliates’ possession or control (except to the extent Xencor retains any license or other right granted by INmune hereunder), and provide written certification of such destruction, or prepare such tangible items of such Confidential Information for shipment to the other Party, at the other Party’s expense; provided that each Party may retain one copy of such Confidential Information for its legal archives subject to a continuing obligation of confidentiality.
